Hangzhou Hezekunyuan Pharmaceutical Co., Ltd.

Main study objectives To study the pharmacokinetics of the test preparation succinate enteric-coated tablets (specification: 0.5g, provided by the registrant Hangzhou Heze Kunyuan Pharmaceutical Co., Ltd. (manufacturer: Jiangsu Hechen Pharmaceutical Co., Ltd.)) and the reference preparation succinate enteric-coated tablets (Simetai®, specification: 0.5g; ABBOTT LABORATORIES certified, provided by Hangzhou Heze Kunyuan Pharmaceutical Co., Ltd.) in healthy adult subjects after a single oral administration under fasting conditions, and to evaluate the bioequivalence of the two preparations when taken orally under fasting conditions. Secondary study objectives To study the safety of the test preparation succinate enteric-coated tablets and the reference preparation succinate enteric-coated tablets (Simetai®) in healthy adult subjects.

The pharmacokinetic behavior of the test formulation (T) bilastine orally disintegrating tablets (specification: 10 mg; produced and provided by Jiangsu Hechen Pharmaceutical Co., Ltd.) and the reference formulation (R) bilastine orally disintegrating tablets (Bilaxten®, specification: 10 mg; licensed by Menarini International Operations Luxembourg S.A.; provided by Jiangsu Hechen Pharmaceutical Co., Ltd.) after a single oral dose in healthy adult subjects under fasting conditions was studied, and the bioequivalence of the two formulations after oral administration under fasting conditions was evaluated.

Main study objectives To study the pharmacokinetics of the test pentoxifylline sustained-release tablets (specification: 0.4g, produced and provided by Jiangsu Hechen Pharmaceutical Co., Ltd.) and the reference pentoxifylline sustained-release tablets (trade name: Trental®, specification: 400 mg, Sanofi-Aventis Deutschland GmbH) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after fasting and fed oral administration. Secondary study objectives To evaluate the safety of the test pentoxifylline sustained-release tablets and the reference pentoxifylline sustained-release tablets (Trental®) in Chinese healthy subjects after a single oral administration in the fasting and fed state.